Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disulfiram plus zinc versus metronidazole for Entamoeba histolytica diarrhea
ISRCTN15356736Phase 2Recruiting
- Sponsor
- University of Florida
- Start
- Aug 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of disulfiram, zinc gluconate and metronidazole in amebiasis (3 arms), sponsored by University of Florida. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Started Aug 2026; status: recruiting.
02
Drugs
disulfiramzinc gluconatemetronidazole
03
Conditions
amebiasis
Beyond the preview
Go deeper on ISRCTN15356736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15356736.